Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics - Takeaways - MDSpire

Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics

  • By

  • Mindong Mi

  • Tianhuan Xiong

  • Jiyong Gong

  • Weijie Sun

  • Tunguang Xu

  • Qifeng Jiang

  • Danqing Zhang

  • Junge Zhang

  • Jiancheng Huang

  • Wei Liang

  • June 22, 2026

  • 0 min

Share

  • 1

    The study enrolled 200 participants, including healthy controls and type 2 diabetes patients stratified by urinary albumin-to-creatinine ratio.

  • 2

    UTRF and UIgG showed excellent diagnostic value for diabetic kidney disease, with AUCs of 0.926 and 0.916, respectively.

  • 3

    A combination of 20 urinary amino acids demonstrated outstanding diagnostic performance with an AUC of 0.928, surpassing individual markers.

  • 4

    SERPINA1 was identified as a key protein biomarker for diabetic kidney disease, with a diagnostic capability AUC of 0.964.

  • 5

    The study emphasizes the need for novel biomarkers to improve the early diagnosis and management of diabetic kidney disease.

Original Source(s)

Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics

  • by Mindong Mi, Tianhuan Xiong, Jiyong Gong, Weijie Sun, Tunguang Xu, Qifeng Jiang, Danqing Zhang, Junge Zhang, Jiancheng Huang, Wei Liang

  • June 22, 2026

Related Content

Early Proteomic and Metabolomic Signatures in Diabetes Associated with Progression to Diabetic Retinopathy Over 1–2 Years

AACE 2026: Will AI replace endocrinologists?

The same technology drawing patients away from clinic may also improve the patient-physician relationship.

A machine learning model for diabetic retinopathy risk stratification using routine blood and urine parameters: insights into kidney-eye crosstalk